Editor's Audio Summary by Anne Rentoumis Cappola, MD, ScM, Associate Editor, the Journal of the American Medical Association, for the June 11, 2014 issue
In a double-blind randomized clinical trial of 2159 infants with HLA-conferred disease susceptibility and a first-degree relative with type 1 diabetes, The TRIGR Study Group tests the hypothesis that weaning to an extensively hydrolyzed formula decreases the cumulative incidence of diabetes-associated autoantibodies, May 2002-April 2013 at 78 study centers in 15 countries.
In a retrospective cohort study of veterans with diabetes initially treated with metformin, Roumie and coauthors compared time to acute myocardial infarction, stroke, or death in patients who added insulin or a sulfonylurea.
Sjöström and coauthors performed a very long-term follow-up observational study of Swedish Obese Subjects participants to investigate diabetes outcomes after bariatric surgery. They determined the long-term diabetes remission rates and the cumulative incidence of microvascular and macrovascular diabetes complications among 603 patients who had type 2 diabetes at baseline.
Florez and colleagues performed whole-exome sequencing on DNA samples from 3756 individuals of Mexican and US Latino ancestry (1794 with type 2 diabetes, 1962 controls) and identified a single low-frequency variant (pE508K) in HNF1A—the Maturity Onset Diabetes of the Young type 3 gene—associated with type 2 diabetes in this population.
Wallia and Molitch review currently available insulin therapy, as well as evidence on the use, application, initiation, and intensification of insulin in the outpatient setting.